SYRS Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 108543 min ago

@ $7.03

Ausgestellt: 14 Feb 2024 @ 15:30

Rendite: -23.47%

Vorheriges Signal: Feb 13 - 15:30

Vorheriges Signal: Kaufen

Rendite: 3.84 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines...

Stats
Tagesvolumen	113 591
Durchschnittsvolumen	207 780
Marktkapitalisierung	143.80M
EPS	$0 ( 2024-03-27 )
Nächstes Ertragsdatum	( $-0.890 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.930
ATR14	$0.0200 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Roth David	Sell	10 451	Common Stock
2024-03-31	Stephens Kristin	Buy	11 666	Common Stock
2024-04-01	Stephens Kristin	Sell	4 218	Common Stock
2024-03-31	Stephens Kristin	Sell	11 666	Restricted Stock Units
2024-03-31	Stephens Kristin	Buy	2 000	Common Stock

INSIDER POWER
54.80
Last 100 transactions
Buy: 2 824 203 \| Sell: 497 307

Volumen Korrelation

Lang: 0.11 (neutral)

Kurz: 0.86 (strong)

Signal:(59.507) Same movement expected

Syros Pharmaceuticals Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Syros Pharmaceuticals Inc Korrelation - Währung/Rohstoff

-0.49
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.42
( neutral )

-0.15
( neutral )

0.03
( neutral )

Syros Pharmaceuticals Inc Finanzdaten

Annual	2023
Umsatz:	$9.94M
Bruttogewinn:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2023
Umsatz:	$9.94M
Bruttogewinn:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2022
Umsatz:	$14.88M
Bruttogewinn:	$11.91M (80.06 %)
EPS:	$-3.90

FY	2021
Umsatz:	$23.49M
Bruttogewinn:	$23.49M (100.00 %)
EPS:	$-18.80

Financial Reports:

No articles found.

Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.